Infants' immune systems are still developing, and their airways are physically tiny.
As the Southern Hemisphere enters its peak season for respiratory illness, Brazil is confronting a concentrated surge of Severe Acute Respiratory Syndrome among its most vulnerable infants, driven primarily by the respiratory syncytial virus. The Oswaldo Cruz Foundation's latest data reveals a country where the youngest and the oldest bear the heaviest burden — RSV filling pediatric wards while influenza claims lives among the elderly. In a nation spanning from the Amazon to the southern plains, with ten states now at high risk and every other on alert, the question is not whether the season will deepen, but whether prevention can outpace it.
- RSV is overwhelming infant wards across Brazil, accounting for 41.5% of confirmed severe respiratory cases in children under two in just the past four weeks.
- The crisis is geographically vast — ten states are classified as high-risk and fourteen more are trending upward, leaving no region of the country untouched.
- A second, quieter emergency runs parallel: influenza A is responsible for 51.7% of recent SRAG deaths, striking hardest among the elderly rather than the young.
- Brazil has already recorded 2,660 SRAG deaths in 2026, with laboratory-confirmed cases spanning RSV, influenza, rhinovirus, and COVID-19 in shifting proportions.
- Health authorities are racing to expand vaccination — flu shots for priority groups nationwide, an RSV vaccine for pregnant women from week 28, and monoclonal antibodies for premature infants most at risk.
Across Brazil, hospitals are registering a sharp rise in severe respiratory illness among infants, with respiratory syncytial virus — RSV — identified as the leading cause. In the past four weeks, RSV accounted for 41.5% of confirmed Severe Acute Respiratory Syndrome cases in children under two, inflaming small airways in a condition known as bronchiolitis that strikes hardest at the very young. Influenza A follows at 27.2% and rhinovirus at 25.5%, while older children and adults remain comparatively stable.
The warning comes from the InfoGripe bulletin, published this week by the Oswaldo Cruz Foundation, Brazil's foremost public health research institution. It arrives as the Southern Hemisphere moves into peak respiratory virus season — a period the Pan American Health Organization flagged last month, specifically naming RSV and the H3N2 influenza strain as primary threats.
The burden, however, is not uniform. Among deaths, influenza A tells a different story: it is responsible for 51.7% of confirmed SRAG fatalities in the past four weeks, with those deaths concentrated among the elderly. Year-to-date, Brazil has recorded 2,660 SRAG deaths overall, with influenza accounting for 39.6% of laboratory-confirmed cases, followed by COVID-19 at 26%, rhinovirus at 21.3%, and RSV at 6.4%.
The geographic spread is sweeping. Ten states — stretching from Acre and Amazonas in the North to Minas Gerais in the Southeast and Paraíba in the Northeast — are now classified as high-risk. Fourteen additional states show rising trajectories, and every state in the country is on alert.
Researcher Tatiana Portella of the InfoGripe team stresses that vaccination remains the primary defense. The public health system offers flu immunization nationwide, prioritizing the elderly, pregnant women, young children, and those with chronic conditions. An RSV vaccine is now available for pregnant women from week 28 of pregnancy, designed to shield newborns after birth, while premature infants at high risk can receive monoclonal antibodies. With 57,585 SRAG cases recorded so far in 2026, the central challenge is whether immunization rates can keep pace as the season intensifies.
Across Brazil, hospitals are seeing a sharp climb in severe respiratory illness among the youngest patients. In the past four weeks alone, respiratory syncytial virus—RSV—has been the culprit in 41.5% of confirmed cases of Severe Acute Respiratory Syndrome, or SRAG, in children under two years old. The virus inflames the small airways deep in the lungs, a condition called bronquiolitis that strikes hardest at infants. Influenza A follows at 27.2% of cases, with rhinovirus at 25.5%. Older children and adults are holding steady; the surge is concentrated in the very young.
The data comes from the InfoGripe bulletin, released this week by the Oswaldo Cruz Foundation, Brazil's leading public health research institution. The picture it paints is one of a country moving into the peak season for respiratory viruses in the Southern Hemisphere—a time when these pathogens circulate most freely. The Pan American Health Organization flagged this shift at the end of last month, specifically naming RSV and the H3N2 strain of influenza as the main threats.
But the danger is not evenly distributed. While RSV dominates among infants, influenza tells a different story when it comes to death. Of the confirmed SRAG deaths in the past four weeks, influenza A was responsible for 51.7%—and those deaths cluster among the elderly. Year-to-date, Brazil has recorded 2,660 SRAG deaths overall, with 1,151 confirmed by laboratory testing. Influenza accounts for 39.6% of those lab-confirmed deaths, followed by COVID-19 at 26%, rhinovirus at 21.3%, and RSV at 6.4%.
The geographic reach is broad. Ten states are now classified as high-risk: Acre, Amazonas, Pará, and Tocantins in the North; Mato Grosso, Goiás, Distrito Federal, and Mato Grosso do Sul in the Center-West; Minas Gerais in the Southeast; and Paraíba in the Northeast. Fourteen states show upward trajectories in case counts over the coming weeks, spanning from the Amazon basin to the southern states of Paraná, Santa Catarina, and Rio Grande do Sul. Every state in Brazil is now on alert.
Vaccination emerges as the primary shield. Tatiana Portella, a researcher with the InfoGripe bulletin and the Fiocruz scientific computing program, emphasizes that immunization is the main way to prevent severe illness and death from both RSV and influenza A. The public health system offers flu vaccine nationwide, prioritizing the elderly, pregnant women, children under six, and people with chronic conditions or other vulnerabilities. For RSV, a vaccine is now available for pregnant women starting at week 28 of pregnancy, designed to protect newborns after birth. Additionally, the health system provides a monoclonal antibody—ready-made immune proteins—to premature infants at high risk of RSV complications.
So far in 2026, Brazil has recorded 57,585 cases of SRAG, with 45.7% testing positive for a respiratory virus. Over the full year, rhinovirus has been the most common, present in 36.1% of identified samples, trailed by influenza A at 26.3%, RSV at 25.3%, and COVID-19 at 7.4%. But these proportions shift dramatically when measuring mortality. The challenge now is whether vaccination rates can keep pace with the virus's spread as the season deepens.
Citações Notáveis
The primary form of prevention against severe illness and death from RSV and influenza A is vaccination, especially for people at higher risk.— Tatiana Portella, Fiocruz researcher
A Conversa do Hearth Outra perspectiva sobre a história
Why is RSV hitting infants so much harder than other age groups?
RSV attacks the smallest airways in the lungs—the bronchioles. Infants' immune systems are still developing, and their airways are physically tiny. When inflammation sets in, it can block airflow quickly. Older children and adults have larger airways and more mature immunity, so they handle it differently.
But the data shows influenza is killing more people overall. Why the difference?
Influenza is devastating to the elderly—their immune systems are weakened by age. RSV is dangerous to infants because of immaturity; influenza is dangerous to the old because of decline. Two different vulnerabilities, two different death patterns.
Ten states at high risk, fourteen showing upward trends. That's most of the country.
Yes. And they're not clustered in one region. You've got the Amazon, the Center-West, the Southeast, the South all lighting up at once. This is a nationwide seasonal wave, not a localized outbreak.
The vaccine for RSV is only for pregnant women. What about babies already born?
That's where the monoclonal antibody comes in—for premature infants especially. But most full-term newborns born to vaccinated mothers get passive protection through antibodies passed from mother to child. It's not perfect, but it's something.
If 45.7% of cases test positive for a virus, what about the other 54%?
They're either viral cases that couldn't be identified, or they're bacterial, or the cause is unclear. The positive cases are the ones we can track and understand. The rest remain in the fog.
What happens if vaccination rates don't climb?
You see what's already happening—more severe cases, more hospitalizations, more deaths in the vulnerable groups. The virus doesn't wait for perfect coverage. It spreads through the gaps.